Prescription medication misuse among opioid dependent patients seeking inpatient detoxification

American Journal on Addictions

Volumn 24, Issue 2, 2015, Pages 173-177

  Wilens, Timothy ^a,b   Zulauf, Courtney ^a   Ryland, Denece ^b   Carrellas, Nicholas ^a   Catalina Wellington, Isela ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Bay Cove Human Services Andrew House Detoxification Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMPHETAMINE; CLONAZEPAM; CLONIDINE; GABAPENTIN; PREGABALIN; PRESCRIPTION DRUG; PSYCHOTROPIC AGENT;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; DEMOGRAPHY; DRUG DETOXIFICATION; DRUG MISUSE; FEMALE; HELP SEEKING BEHAVIOR; HUMAN; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; PRESCRIPTION; PROSPECTIVE STUDY; QUALITATIVE ANALYSIS; SELF-CONCEPT ASSESSMENT; UNLICENSED DRUG USE; ALCOHOLISM; HOSPITAL PATIENT; PSYCHOLOGY; SELF MEDICATION; SELF REPORT; YOUNG ADULT;

ADULT; ALCOHOLISM; FEMALE; HUMANS; INPATIENTS; MALE; OPIOID-RELATED DISORDERS; PRESCRIPTION DRUGS; PSYCHOTROPIC DRUGS; SELF MEDICATION; SELF REPORT; YOUNG ADULT;

EID: 84927136840     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1111/ajad.12159     Document Type: Article

References (31)

1. Centers for Disease Control and Prevention. Opioids drive continued increase in drug overdose deaths. Atlanta, GA: Centers for Disease Control and Prevention; 2013.
2. Franklin GM, Mai J, Turner J, et al. Bending the prescription opioid dosing and mortality curves: Impact of the Washington State opioid dosing guideline. Am. J. Ind. Med. 2012; 55: 325-331.
3. Center for Disease Control. Vital signs: Overdoses of prescription opioid pain relievers-United States, 1999-2008. MMWR Surveill. Summ. 2011; 60: 1-6.
4. Substance Abuse and Mental Health Services Administration. Drug Abuse Warning Network: Selected Tables of National Estimates of Drug-Related Emergency Department Visits. In: Center for Behavioral Health Statistics and Quality S, ed. Rockville, MD: 2010.
5. Center for Disease Control and Prevention. Drug Overdose in the United States: Fact Sheet. 2014; http://www.cdc.gov/homeandrecreationalsafety/overdose/facts.html. Accessed May 20, 2014.
6. National Center for Injury Prevention and Control. Policy impact: Prescription painkiller overdoses. Centers for Disease Control and Prevention; 2011.
7. Warner M, Chen LH, Makuc DM., Increase in fatal poisonings involving opioid analgesics in the United States, 1999-2006. NCHS Data Brief. 2009; 22: 1-8.
8. Jones CM, Mack KA, Paulozzi LJ., Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013; 309: 657-659.
9. Raza S, Siddiqui UA, Megna JL, et al. Pregabalin treatment of anxiety in patients with substance use disorders. Ann. Pharmacother. 2010; 44: 937-938.
10. Palumbo DR, Sallee FR, Pelham WE Jr, et al. Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J. Am. Acad. Child Adolesc. Psychiatry. 2008; 47: 180-188.
11. Blanco C, Raza MS, Schneier FR, et al. The evidence-based pharmacological treatment of social anxiety disorder. Int. J. Neuropsychopharmacol. 2003; 6: 427-442.
12. Jones HE, Johnson RE, Jasinski DR, et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: Effects on the neonatal abstinence syndrome. Drug Alcohol Depend. 2005; 79: 1-10.
13. Minozzi S, Amato L, Davoli M., Detoxification treatments for opiate dependent adolescents. Cochrane Database Syst. Rev. 2009; 4: CD006749.
14. Ziedonis DM, Amass L, Steinberg M, et al. Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence. Drug Alcohol Depend. 2009; 99: 28-36.
15. Fischer B, Lusted A, Roerecke M, et al. The prevalence of mental health and pain symptoms in general population samples reporting nonmedical use of prescription opioids: A systematic review and meta-analysis. J. Pain. 2012; 13: 1029-1044.
16. Wilens TE, O'Keefe J, O'Connell JJ, et al. A dual diagnosis detoxification unit: I. Organization and structure. Am. J. Addict. 1993; 2: 91-98.
17. Wilens TE, O'Keefe J, O'Connell JJ, et al. A public dual diagnosis detoxification unit: II. Observations of 70 dually diagnosed patients. Am. J. Addict. 1993; 2: 1-13.
18. Johansson BA, Berglund M, Hanson M, et al. Dependence on legal psychotropic drugs among alcoholics. Alcohol Alcohol. 2003; 38: 613-618.
19. Price AM, Ilgen MA, Bohnert AS., Prevalence and correlates of nonmedical use of prescription opioids in patients seen in a residential drug and alcohol treatment program. J. Subst. Abuse Treat. 2011; 41: 208-214.
20. Ives TJ, Chelminski PR, Hammett-Stabler CA, et al. Predictors of opioid misuse in patients with chronic pain: A prospective cohort study. BMC Health Serv. Res. 2006; 6: 46.
21. Morasco BJ, Dobscha SK., Prescription medication misuse and substance use disorder in VA primary care patients with chronic pain. Gen. Hosp. Psychiatry. 2008; 30: 93-99.
22. Baird CR, Fox P, Colvin LA., Gabapentinoid abuse in order to potentiate the effect of methadone: A survey among substance misusers. Eur. Addict. Res. 2014; 20: 115-118.
23. Eckhardt K, Ammon S, Hofmann U, et al. Gabapentin enhances the analgesic effect of morphine in healthy volunteers. Anesth. Anal. 2000; 91: 185-191.
24. Gautier PE, De Kock M, Fanard L, et al. Intrathecal clonidine combined with sufentanil for labor analgesia. Anesthesiology. 1998; 88: 651-656.
25. Dalal S, Melzack R., Potentiation of opioid analgesia by psychostimulant drugs: A review. J. Pain Symptom Manage. 1998; 16: 245-253.
26. Merlo LJ, Singhakant S, Cummings SM, et al. Reasons for misuse of prescription medication among physicians undergoing monitoring by a physician health program. J. Addict. Med. 2013; 7: 349-353.
27. Darke S., Opioid overdose and the power of old myths: What we thought we knew, what we do know and why it matters. Drug Alcohol Rev. 2014; 33: 109-114.
28. Darke S, Duflou J, Torok M., The comparative toxicology and major organ pathology of fatal methadone and heroin toxicity cases. Drug Alcohol Depend. 2010; 106: 1-6.
29. Britton PC, Wines JD Jr, Conner KR., Non-fatal overdose in the 12 months following treatment for substance use disorders. Drug Alcohol Depend. 2010; 107: 51-55.
30. Dhalla IA, Mamdani MM, Sivilotti ML, et al. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. CMAJ. 2009; 181: 891-896.
31. Core Competencies for Intra-Nasal Naloxone Distribution Pilot Program Participants. In: Health BoSASwtMDoP, ed 2014.